Liraglutide was as effective as a structured supervised lifestyle modification programme combining diet and exercise for reducing weight, liver damage, and liver fat at 26 weeks in obese Asians with nonalcoholic fatty liver disease (NAFLD), a study shows.
While liraglutide successfully induces weight loss in obese adults with nonalcoholic fatty liver disease (NAFLD), its benefits were not preserved after discontinuation, unlike that of lifestyle modification, according to a new Singapore study.
A once-daily oral dose of sofosbuvir and velpatasvir for 12 weeks leads to sustained virological response (SVR) in a majority of patients with chronic hepatitis C virus (HCV) infection, according to an Asian study. However, the efficacy of this regimen may be reduced in patients with HCV genotype 3b with cirrhosis.
Systemic administration of the gene therapy scAAV2/8-LP1-hFIXco to patients with severe haemophilia B led to stable therapeutic expression of the factor IX gene over 8 years without evidence of late toxicities from treatment, according to a long-term follow-up study.
Treatment with ramucirumab, a human IgG1 monoclonal antibody, significantly improves overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) in both Asians and non-Asians, based on a pooled analysis of REACH* and REACH-2** studies presented at ESMO Asia 2018.
Treatment with the combination of the DAAs* glecaprevir and pibrentasvir led to sustained virological response (SVR) in a majority of patients with chronic hepatitis C virus (HCV) infection genotype 5 or 6, according to the phase IIIB ENDURANCE-5,6** trial.
Treatment with the tyrosine kinase inhibitor cabozantinib led to improved tumour response, in terms of target lesion regression, alpha-fetoprotein (AFP) response, and time to disease progression compared with placebo in patients with advanced hepatocellular carcinoma (HCC) who had prior treatment with sorafenib, according to the CELESTIAL* trial presented at ESMO Asia 2018.
The patient profiles of individuals diagnosed with hepatocellular carcinoma (HCC) vary depending on whether the cause of HCC is hepatitis B virus (HBV) infection or cryptogenic, a Singapore study found.
Most liver tumours may be identified at early stages in cirrhotic patients treated with direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection, a study reports. Risk factors for increased risk of hepatocellular carcinoma following DAA therapy include male sex, diabetes and noninvasive markers of liver fibrosis.